Pfizer Inc. (NYSE:PFE) is named one of the 10 Best Affordable Stocks Under $50 to Buy. Morgan Stanley raised its price target for Pfizer from $32 to $33 with an Equalweight rating after the company’s Q2 2025 earnings report.

The new price target considers the impact of tariffs from China, Canada, and Mexico on Pfizer’s guidance. The company also took into account potential price changes following a letter from President Trump.

Pfizer reaffirmed its full-year 2025 revenue guidance and increased its adjusted diluted EPS forecast by $0.10, ranging from $2.90 to $3.10. This update is supported by Pfizer’s strong performance, confidence in the business, and other factors.

Pfizer is a prominent pharmaceutical company known for its healthcare products, medicines, and vaccines. While Pfizer shows promise as an investment, some AI stocks may offer greater potential with less risk.

For more information on stocks with strong revenue growth and under-the-radar stocks, visit Insider Monkey’s website. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Morgan Stanley Lifts Pfizer (PFE) Price Target, Keeps Equalweight Rating